260 related articles for article (PubMed ID: 21384849)
1. Estimating toxicity-related biological pathway altering doses for high-throughput chemical risk assessment.
Judson RS; Kavlock RJ; Setzer RW; Hubal EA; Martin MT; Knudsen TB; Houck KA; Thomas RS; Wetmore BA; Dix DJ
Chem Res Toxicol; 2011 Apr; 24(4):451-62. PubMed ID: 21384849
[TBL] [Abstract][Full Text] [Related]
2. Integration of dosimetry, exposure, and high-throughput screening data in chemical toxicity assessment.
Wetmore BA; Wambaugh JF; Ferguson SS; Sochaski MA; Rotroff DM; Freeman K; Clewell HJ; Dix DJ; Andersen ME; Houck KA; Allen B; Judson RS; Singh R; Kavlock RJ; Richard AM; Thomas RS
Toxicol Sci; 2012 Jan; 125(1):157-74. PubMed ID: 21948869
[TBL] [Abstract][Full Text] [Related]
3. Incorporating population variability and susceptible subpopulations into dosimetry for high-throughput toxicity testing.
Wetmore BA; Allen B; Clewell HJ; Parker T; Wambaugh JF; Almond LM; Sochaski MA; Thomas RS
Toxicol Sci; 2014 Nov; 142(1):210-24. PubMed ID: 25145659
[TBL] [Abstract][Full Text] [Related]
4. Metabolism, variability and risk assessment.
Dorne JL
Toxicology; 2010 Feb; 268(3):156-64. PubMed ID: 19932147
[TBL] [Abstract][Full Text] [Related]
5. Ethyl methanesulfonate toxicity in Viracept--a comprehensive human risk assessment based on threshold data for genotoxicity.
Müller L; Gocke E; Lavé T; Pfister T
Toxicol Lett; 2009 Nov; 190(3):317-29. PubMed ID: 19443141
[TBL] [Abstract][Full Text] [Related]
6. Implementing Toxicity Testing in the 21st Century (TT21C): Making safety decisions using toxicity pathways, and progress in a prototype risk assessment.
Adeleye Y; Andersen M; Clewell R; Davies M; Dent M; Edwards S; Fowler P; Malcomber S; Nicol B; Scott A; Scott S; Sun B; Westmoreland C; White A; Zhang Q; Carmichael PL
Toxicology; 2015 Jun; 332():102-11. PubMed ID: 24582757
[TBL] [Abstract][Full Text] [Related]
7. Advancing exposure characterization for chemical evaluation and risk assessment.
Cohen Hubal EA; Richard A; Aylward L; Edwards S; Gallagher J; Goldsmith MR; Isukapalli S; Tornero-Velez R; Weber E; Kavlock R
J Toxicol Environ Health B Crit Rev; 2010 Feb; 13(2-4):299-313. PubMed ID: 20574904
[TBL] [Abstract][Full Text] [Related]
8. Physiological-model-based derivation of the adult and child pharmacokinetic intraspecies uncertainty factors for volatile organic compounds.
Pelekis M; Gephart LA; Lerman SE
Regul Toxicol Pharmacol; 2001 Feb; 33(1):12-20. PubMed ID: 11259175
[TBL] [Abstract][Full Text] [Related]
9. Quantitative in vitro-to-in vivo extrapolation in a high-throughput environment.
Wetmore BA
Toxicology; 2015 Jun; 332():94-101. PubMed ID: 24907440
[TBL] [Abstract][Full Text] [Related]
10. Relative impact of incorporating pharmacokinetics on predicting in vivo hazard and mode of action from high-throughput in vitro toxicity assays.
Wetmore BA; Wambaugh JF; Ferguson SS; Li L; Clewell HJ; Judson RS; Freeman K; Bao W; Sochaski MA; Chu TM; Black MB; Healy E; Allen B; Andersen ME; Wolfinger RD; Thomas RS
Toxicol Sci; 2013 Apr; 132(2):327-46. PubMed ID: 23358191
[TBL] [Abstract][Full Text] [Related]
11. Chloroform mode of action: implications for cancer risk assessment.
Golden RJ; Holm SE; Robinson DE; Julkunen PH; Reese EA
Regul Toxicol Pharmacol; 1997 Oct; 26(2):142-55. PubMed ID: 9356278
[TBL] [Abstract][Full Text] [Related]
12. Computational toxicology as implemented by the U.S. EPA: providing high throughput decision support tools for screening and assessing chemical exposure, hazard and risk.
Kavlock R; Dix D
J Toxicol Environ Health B Crit Rev; 2010 Feb; 13(2-4):197-217. PubMed ID: 20574897
[TBL] [Abstract][Full Text] [Related]
13. Virtual tissues in toxicology.
Shah I; Wambaugh J
J Toxicol Environ Health B Crit Rev; 2010 Feb; 13(2-4):314-28. PubMed ID: 20574905
[TBL] [Abstract][Full Text] [Related]
14. Quantitative in vitro to in vivo extrapolation of cell-based toxicity assay results.
Yoon M; Campbell JL; Andersen ME; Clewell HJ
Crit Rev Toxicol; 2012 Sep; 42(8):633-52. PubMed ID: 22667820
[TBL] [Abstract][Full Text] [Related]
15. Impact of inter-individual differences in drug metabolism and pharmacokinetics on safety evaluation.
Dorne JL
Fundam Clin Pharmacol; 2004 Dec; 18(6):609-20. PubMed ID: 15548231
[TBL] [Abstract][Full Text] [Related]
16. Chemical-specific screening criteria for interpretation of biomonitoring data for volatile organic compounds (VOCs)--application of steady-state PBPK model solutions.
Aylward LL; Kirman CR; Blount BC; Hays SM
Regul Toxicol Pharmacol; 2010 Oct; 58(1):33-44. PubMed ID: 20685286
[TBL] [Abstract][Full Text] [Related]
17. Human variability in xenobiotic metabolism and pathway-related uncertainty factors for chemical risk assessment: a review.
Dorne JL; Walton K; Renwick AG
Food Chem Toxicol; 2005 Feb; 43(2):203-16. PubMed ID: 15621332
[TBL] [Abstract][Full Text] [Related]
18. Cellular stress response pathway system as a sentinel ensemble in toxicological screening.
Simmons SO; Fan CY; Ramabhadran R
Toxicol Sci; 2009 Oct; 111(2):202-25. PubMed ID: 19567883
[TBL] [Abstract][Full Text] [Related]
19. Investigation of the potential impact of benchmark dose and pharmacokinetic modeling in noncancer risk assessment.
Clewell HJ; Gentry PR; Gearhart JM
J Toxicol Environ Health; 1997 Dec; 52(6):475-515. PubMed ID: 9397182
[TBL] [Abstract][Full Text] [Related]
20. Computational systems biology and dose-response modeling in relation to new directions in toxicity testing.
Zhang Q; Bhattacharya S; Andersen ME; Conolly RB
J Toxicol Environ Health B Crit Rev; 2010 Feb; 13(2-4):253-76. PubMed ID: 20574901
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
